Prothena speaking to advisers about potential sale, Bloomberg says

Prothena is preparing for a potential sale ahead of key Alzheimer’s data expected in the coming months, Michelle Davis, Dinesh Nair and Manuel Baigorri of Bloomberg report, citing people with knowledge of the matter. The company has been speaking to advisers as it gets ready to explore strategic options that may include a sale or partnership, sources told Bloomberg. The people added that Prothena would likely attract interest from large drugmakers. Deliberations are at an early stage, and Prothena could opt to remain independent for longer, the sources added. Shares of Prothena jumped 11% to $49.05 before halting for volatility following the report.